Wild-type (senile) amyloidosis pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 14: Line 14:
*In systemic amyloidosis, [[amyloid]] gradually accumulates and [[amyloid]] deposition is widespread in the viscera, [[blood vessel]] walls, and different [[Connective tissue|connective tissues]].<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref>
*In systemic amyloidosis, [[amyloid]] gradually accumulates and [[amyloid]] deposition is widespread in the viscera, [[blood vessel]] walls, and different [[Connective tissue|connective tissues]].<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref>
===Pathogenesis===
===Pathogenesis===
* Wild-type (senile) amyloidosis is a type of systemic amyloidosis.
* Wild-type (senile) amyloidosis is a type of systemic amyloidosis as transthyretin (TTR) deposits can be found throughout the body.
* The culprit protein responsible for the disease is transthyretin (TTR) and it is deposited in the non-mutated form, hence the name "Wild-type".
* The culprit protein responsible for the disease is TTR and it is deposited in the non-mutated form, hence the name "Wild-type".
* The normal TTR protein compared with the mutated form is less likely to get deposited and to cause a pathology
*TTR results in pathologies due to misfolding, breaking apart, and deposition of the amyloid fibrils in healthy tissue.
* The normal TTR protein, compared with the mutated form, is less likely to get deposited and cause pathology.
*This is believed to be the reason as to why this condition almost always affects the elderly (65 years of age or older).
*The condition mainly affects the heart. However, other organ systems, such as the nervous and musculoskeletal systems, can also be involved.
 
== Genetics ==
 
* There are no genes implicated in the causality of wild-type (senile) amyloidosis.
 
== Associated Conditions ==
 
* Aging is very strongly associated with wild-type (senile) amyloidosis.


==References==
==References==

Revision as of 16:27, 17 December 2019

Wild-type (senile) amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Wild-type (senile) amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Wild-type (senile) amyloidosis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Wild-type (senile) amyloidosis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wild-type (senile) amyloidosis pathophysiology

CDC on Wild-type (senile) amyloidosis pathophysiology

Wild-type (senile) amyloidosis pathophysiology in the news

Blogs on Wild-type (senile) amyloidosis pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Wild-type (senile) amyloidosis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

Pathophysiology

  • Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes.[1]
  • These abnormal amyloids are derived from misfolding and aggregation of normally soluble proteins.
  • Amyloid deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.[2]

Systemic Amyloidosis

Pathogenesis

  • Wild-type (senile) amyloidosis is a type of systemic amyloidosis as transthyretin (TTR) deposits can be found throughout the body.
  • The culprit protein responsible for the disease is TTR and it is deposited in the non-mutated form, hence the name "Wild-type".
  • TTR results in pathologies due to misfolding, breaking apart, and deposition of the amyloid fibrils in healthy tissue.
  • The normal TTR protein, compared with the mutated form, is less likely to get deposited and cause pathology.
  • This is believed to be the reason as to why this condition almost always affects the elderly (65 years of age or older).
  • The condition mainly affects the heart. However, other organ systems, such as the nervous and musculoskeletal systems, can also be involved.

Genetics

  • There are no genes implicated in the causality of wild-type (senile) amyloidosis.

Associated Conditions

  • Aging is very strongly associated with wild-type (senile) amyloidosis.

References

  1. Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
  2. Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
  3. Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
  4. Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.